REG - Aptamer Group PLC - Second Phase of Alzheimer's test with Neuro-Bio

AptamerAnnouncement

22/02/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240222:nRSV0115Ea&default-theme=true

RNS Number : 0115E  Aptamer Group PLC  22 February 2024

22 February 2024

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

Aptamer and Neuro-Bio enter the second phase of Alzheimer's test development

 

Aptamer Group plc (AIM: APTA), the developer of novel Optimer(®) binders
to enable innovation in the life sciences industry, announces the second phase
of its on-going partnership with Neuro-Bio, an Oxfordshire-based biotechnology
company with a therapeutic focus on neurodegenerative disease, to develop
Optimer binders for a lateral flow test for the early diagnosis of Alzheimer's
disease.

 

This latest phase involves development of an additional Optimer binder against
the innovative Neuro-Bio target implicated in Alzheimer's disease, with the
goal of developing reagents for a lateral flow test for early disease
detection. Following the earlier identification of Optimer binders to this
novel Alzheimer's disease biomarker,(1) these binders have been characterised
for use in lateral flow and biosensor assays.

 

Common lateral flow test formats require a pair of binders to increase
diagnostic test accuracy. To prevent the need for animal-derived antibodies in
its Alzheimer's disease diagnostic, Neuro-Bio now requires the development of
additional binders to support the lateral flow test format and deliver a
wholly Optimer-powered test. As Optimer binders are oligonucleotide-based,
rather than protein-based like antibodies, they offer further advantages
including scalability of manufacture, improved shelf-life and tuneability
benefits that will allow more stable and specific reagents for use in lateral
flow tests.

 

 

Steve Hull, Chairman of Aptamer Group, said: "We are very pleased to continue
our exciting relationship with Neuro-Bio to deliver the specific Optimer
binders needed to enable this revolutionary diagnostic for this devastating
disease. It is great to work with such enthusiastic partners that understand
our Optimer technology's benefits and are actively seeking solutions to
overcome the industry's problems with antibodies."

 

Baroness Susan Greenfield, CEO of Neuro-Bio, said: "At Neuro-Bio we're
thrilled at entering this next phase of development with Aptamer Group: the
first phase proved productive and very promising. Now, this next stage takes
us closer to realising a highly novel and much needed technology for detecting
neurodegenerative diseases at a very early stage."

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION.

 

(1.
https://www.londonstockexchange.com/news-article/APTA/aptamer-neuro-bio-to-develop-alzheimer-s-test/15997896)

- ENDS -

 

For further information, please contact:

 

 

 Aptamer Group plc                                        +44 (0) 1904 217 404

 Steve Hull
 SPARK Advisory Partners Limited - Nominated Adviser      +44 (0) 20 3368 3550

 Andrew Emmott / Mark Brady / Adam Dawes
 Turner Pope Investments (TPI) Limited - Broker           +44 (0) 20 3657 0050

 James Pope / Andrew Thacker

 

About Aptamer Group plc

Aptamer Group develops custom affinity binders through its proprietary
Optimer(®) platform to enable new approaches in therapeutics, diagnostics,
and research applications. The Company strives to deliver transformational
solutions that meet the needs of life science researchers and developers.

Optimer binders are oligonucleotide affinity ligands that can function as an
antibody alternative. The global affinity ligand market is currently worth
over $170 billion.

Aptamer has successfully delivered projects for a range of global pharma
companies, diagnostic development companies, and research institutes, covering
multiple application areas with the objective of establishing royalty-bearing
licenses.

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RESFFFFLFEILFIS